GCM
IBB icon

GKV Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

GKV Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-290
Closed -$37.1K – 126
2025
Q1 		$37.1K Hold
290
– – 0.02% 126
2024
Q4 		$38.3K Buy
+290
New +$40.8K 0.02% 130

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

GKV Capital Management's IBB Position: Q2 2025 in Review

GKV Capital Management sold out of iShares Biotechnology ETF (IBB) in Q2 2025, closing a stake of 290 shares — an estimated $37.1K sold.

GKV Capital Management first reported a position in IBB in Q4 2024 and held it in 2 quarters. The position peaked at $38.3K in Q4 2024. 797 funds tracked by Wall St. Rank hold IBB as of Q2 2025.

  • GKV Capital Management reported no remaining iShares Biotechnology ETF position as of Q2 2025 after selling out during the quarter.
  • GKV Capital Management sold 290 iShares Biotechnology ETF shares in Q2 2025, an estimated $37.1K.
  • GKV Capital Management first reported a position in iShares Biotechnology ETF in Q4 2024 and held it in 2 quarters.
  • GKV Capital Management's iShares Biotechnology ETF position peaked at $38.3K in Q4 2024.
  • 797 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2025.

Based on GKV Capital Management's 13F filing for Q2 2025, filed 11 Aug 2025.